See more : Adara Acquisition Corp. (ADRA) Income Statement Analysis – Financial Results
Complete financial analysis of Silk Road Medical, Inc (SILK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silk Road Medical, Inc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Skydeck Acquisition Corp. (SKYA) Income Statement Analysis – Financial Results
- Vtech Holdings Limited (VTKLF) Income Statement Analysis – Financial Results
- Nozawa Corporation (5237.T) Income Statement Analysis – Financial Results
- Allane SE (0R88.L) Income Statement Analysis – Financial Results
- Anupam Rasayan India Limited (ANURAS.BO) Income Statement Analysis – Financial Results
Silk Road Medical, Inc (SILK)
About Silk Road Medical, Inc
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 177.13M | 138.64M | 101.48M | 75.23M | 63.35M | 34.56M | 14.26M |
| Cost of Revenue | 50.05M | 37.88M | 25.45M | 21.29M | 15.93M | 10.87M | 5.13M |
| Gross Profit | 127.09M | 100.76M | 76.03M | 53.94M | 47.43M | 23.68M | 9.13M |
| Gross Profit Ratio | 71.75% | 72.68% | 74.92% | 71.70% | 74.86% | 68.53% | 64.03% |
| Research & Development | 41.32M | 36.45M | 27.11M | 21.27M | 12.27M | 10.26M | 7.24M |
| General & Administrative | 144.57M | 115.97M | 96.17M | 75.33M | 62.86M | 34.82M | 20.26M |
| Selling & Marketing | 461.00K | 347.00K | 221.00K | 194.00K | 362.00K | 186.00K | 218.00K |
| SG&A | 145.03M | 116.32M | 96.39M | 75.52M | 63.22M | 34.82M | 20.26M |
| Other Expenses | 442.00K | -190.00K | -23.00K | -80.00K | -21.05M | -12.06M | 2.93M |
| Operating Expenses | 186.36M | 152.77M | 123.50M | 96.80M | 75.49M | 45.08M | 27.50M |
| Cost & Expenses | 236.41M | 190.64M | 148.94M | 118.09M | 91.42M | 55.95M | 32.63M |
| Interest Income | 9.96M | 2.53M | 198.00K | 1.10M | 1.66M | 189.00K | 34.00K |
| Interest Expense | 6.87M | 5.10M | 2.52M | 4.41M | 4.95M | 4.36M | 3.94M |
| Depreciation & Amortization | 3.79M | 3.17M | 1.92M | 1.39M | 1.29M | 517.00K | 128.72K |
| EBITDA | -45.08M | -46.74M | -45.55M | -41.47M | -46.17M | -32.75M | -18.25M |
| EBITDA Ratio | -31.32% | -35.82% | -46.61% | -55.51% | -41.68% | -94.78% | -107.20% |
| Operating Income | -59.27M | -52.00M | -47.47M | -42.86M | -28.07M | -21.40M | -18.37M |
| Operating Income Ratio | -33.46% | -37.51% | -46.78% | -56.97% | -44.30% | -61.91% | -128.87% |
| Total Other Income/Expenses | 3.53M | -3.01M | -2.34M | -4.51M | -24.35M | -16.24M | -982.00K |
| Income Before Tax | -55.74M | -55.01M | -49.81M | -47.37M | -52.42M | -37.63M | -19.36M |
| Income Before Tax Ratio | -31.47% | -39.68% | -49.09% | -62.96% | -82.73% | -108.89% | -135.76% |
| Income Tax Expense | 43.00K | 3.01M | 576.00K | 3.02M | 3.66M | -11.87M | 6.87M |
| Net Income | -55.74M | -58.02M | -50.39M | -50.39M | -56.07M | -37.63M | -19.36M |
| Net Income Ratio | -31.47% | -41.85% | -49.65% | -66.98% | -88.51% | -108.89% | -135.76% |
| EPS | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| EPS Diluted | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| Weighted Avg Shares Out | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
| Weighted Avg Shares Out (Dil) | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
Silk Road Medical (SILK) Reports Q1 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) delivered earnings and revenue surprises of -17.07% and 5.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical to Present at the BofA Securities 2022 Healthcare Conference
SUNNYVALE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2022 Healthcare...
Silk Road Medical to Report First Quarter 2022 Financial Results on May 4, 2022
SUNNYVALE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2022 after...
Silk Road Medical, Inc (SILK) CEO Erica Rogers on Q4 2021 Results - Earnings Call Transcript
Silk Road Medical, Inc (SILK) CEO Erica Rogers on Q4 2021 Results - Earnings Call Transcript
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) delivered earnings and revenue surprises of -5% and 8.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
SUNNYVALE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full...
Silk Road Medical to Present at the 11th Annual SVB Leerink Global Healthcare Conference
SUNNYVALE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the 11th Annual SVB Leerink...
Silk Road Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference
SUNNYVALE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan...
Silk Road Medical to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
SUNNYVALE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the...
Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q3 2021 Results - Earnings Call Transcript
Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports